Woodford's funds hit by September biotech sell-off

Manager increases positions on weakness

Daniel Flynn
clock

Neil Woodford's UK Equity Income fund and his Patient Capital investment trust were both hit by a biotech sell-off during a 'weak and volatile' September.

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot